Advertisement

Topics

Search Results for "BIAL Pharmaceuticals"

06:15 EDT 23rd June 2017 | BioPortfolio

Matching Channels

Massachusetts

Located in the north-east corner of the USA, Massachusetts, has the third highest GDP of any state in America and is also a hotspot for the biotechnology industry. In addition to the globally renown...

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...

Michigan

Surrounded by the Great Lakes in the north east of the US, Michigan hosts many high profile biotechnology companies and has become an industry hotbed. In 1993 MichBio was formed, as an industry tr...

Covidien

Covidien is the 9th largest global medical device company with annual sales in 2010 of almost $8 billion. Covidien was originally Tyco Healthcare, until June 2007, and has seen year-on-year growth s...

Matching News

BIAL signs mega-million-$ deal for Parkinson’s drug in North America

USA-based Neurocrine Biosciences and Portuguese pharmaceutical firm BIAL have entered into an exclusive…

BIAL sells allergic immunotherapy business to Roxall

Portuguese pharmaceutical firm BIAL has agreed to sell its allergic immunotherapy business to German…

Neurocrine gets rights to Bial-Portela's PD drug

Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (

Bial and Eisai receive positive opinion for Zebinix to treat focal onset epilepsy

Bial and Eisai have announced the receipt of a positive opinion for Zebinix (eslicarbazepine acetate) from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) to treat...

Neurocrine Nabs BIAL's PD Therapy Opicapone for North America

Neurocrine Biosciences is paying Portuguese firm BIAL $30 million up front for exclusive rights to develop the latter’s EU-approved Parkinson’s disease drug, ONGENTYS® (opicapone), in North A...

Team describes off-target effects of Bial's FAAH inhibitor

Bial Sells Allergic Immunotherapy Business

  Life Sciences Jobs   ...

Neurocrine Biosciences Nabs North American Rights to Bial's ONGENTYS

  Life Sciences Jobs   ...

Matching PubMed Articles

Progress Confirmed for Pharmaceuticals in 2016.

n/a.

Temporal and spatial behavior of pharmaceuticals in Narragansett Bay, Rhode Island, United States.

The behavior and fate of pharmaceutical ingredients in coastal marine ecosystems is not well understood. To address this, the spatial and temporal distribution of 15 high volume pharmaceuticals were m...

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

About fundamentals and sermonizers. Author's response to the letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?"

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement